<DOC>
	<DOCNO>NCT01745354</DOCNO>
	<brief_summary>For patient lymphoma recurs chemotherapy , bone marrow transplantation use cell healthy donor represent potentially curative treatment . In individual , cure possible transplantation healthy donor immune cell fight lymphoma patient . The goal work test strategy activate healthy donor immune cell effectively fight lymphoma result increase cure rate patient . Our group previously study CpG , immune activate medication , patient lymphoma demonstrated modest anti-tumor response . We potent form CpG intend test see well activate donor immune cell result shrinkage tumor throughout entire body , injected site .</brief_summary>
	<brief_title>Immunostimulatory CpG SD-101 + RT Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation ( HCT )</brief_title>
	<detailed_description>Patients receive low dose radiation bulky symptomatic lymph node day -2 -1 . SD-101 administer intratumorally single large palpable node within 24 hour completion radiation , day 0 . Two additional intratumoral SD-101 injection perform day 7 ( +/- 2 day ) 14 ( +/- 2 day ) . This dose range study use 3+3 design definition maximum tolerate dose ( MTD ) group find acceptable past . The first cohort patient receive SD-101 dose 0.3 mg per injection . The dose escalate 1 mg 3 mg base dose limit toxicity ( DLT ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Biopsyconfirmed relapse , refractory , progressive NHL HL ( Refer Section 3.2.1 exclude subtypes ) At least 3 site disease 1 . One diagnosis ( lymph node bone marrow biopsy ) 2 . One palpable treatment 3 . One measurable radiographically &gt; 60 day RIC allogeneic transplant lymphoma 18 year age old Mixed ( 595 % ) complete ( &gt; 95 % ) chimerism Eastern Oncology Cooperative Group ( ECOG ) performance status ≤ 2 ANC &gt; 1000/mm3 , platelet &gt; 50,000/mm3 Total bilirubin ≤ 2.5 mg/dL , AST ALT &lt; 3 time upper limit normal Serum creatinine ≤ 3 mg/dL No chemotherapy , RT , DLI biologic therapy lymphoma least 4 week prior schedule treatment Minimal immunosuppression ( define monotherapy ≤ 10 mg prednisone daily , ≤ 200 mg cyclosporine daily , ≤ 2 mg tacrolimus daily ) least 2 week prior schedule treatment HIV associate lymphoma Acute GVHD time enrollment ( history treat resolve GVHD permit ) Active infection within 14 day prior schedule treatment Active Cytomegalovirus ( CMV ) disease time enrollment Preexisting autoimmune antibody mediate disease ( include systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia ) Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>